May 3, 2010 (FinancialWire) — CPEX Pharmaceuticals, Inc., (NASDAQ: CPEX) has appointed Robert Forrester to its board of directors. In conjunction with the appointment, the company’s board has temporarily expanded the number of seats on the board to six.

According to CPEX, Forrester will stand for election at the company’s annual meeting on May 26, 2010 to replace current director Miguel Fernandez, who has chosen to retire at the end of his term.

Forrester is the chief operating officer of Forma Therapeutics, Inc., a biotech firm. Forrester served in various roles at CombinatoRx, Inc. (NASDAQ: CRXX) from 2004 until January 2010, including as interim president and CEO through CombinatoRx’s merger with Neuromed, a privately held biopharmaceutical company, in December 2009.

New Hampshire-based CPEX Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products utilizing CPEX’s drug delivery platform technology.

CPEX has U.S. and international patents and other proprietary rights to technology meant to facilitate the absorption of drugs. CPEX has licensed applications of its proprietary CPE-215 drug delivery technology to Auxilium Pharmaceuticals, which launched Testim, a topical testosterone gel, in 2003.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [rgltryrtl] [cmplncz] [gvrncnr] [biomedphrm]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.